Biosion Inc., a China-based global clinical stage biotechnology company, announced on Monday that it has named Dr Anthony Yeh as its new chief strategy officer and head of China business development.

In the new role, Dr Yeh is to head corporate strategy, China BD, and capital fundraising and will report to Dr Mingjiu Chen, chief executive officer.

Dr Yeh has served as vice president, head of Corporate Strategy, Investor Relations and Capital Market at CStone Pharmaceuticals (HKSE:2616). He has more than 15 years of experience in healthcare, investment, and management consulting. He has held various leadership roles in helping to build CStone through public listing and eventually to commercialisation stage. He has held the position of regional head of Business Economics and Strategy at Abbott (NYSE: ABT) and engagement manager at LEK Consulting.